to study search History No further version available for comparison

Improving the health of children and adolescents with autoinflammatory diseases

Organizational Data

DRKS-ID:
DRKS00032447
Recruitment Status:
Recruiting planned
Date of registration in DRKS:
2024-01-04
Last update in DRKS:
2024-01-04
Registration type:
Prospective

Acronym/abbreviation of the study

Pro-AID

URL of the study

No Entry

Brief summary in lay language

Autoinflammatory diseases (AIDs) are rare chronic diseases in which recurrent or permanent inflammation occurs due to dysregulation of the innate immune system. Affected children and adolescents are at increased risk for comorbidities and socioeconomic burden. Early therapy with complete inflammation control can prevent organ damage, reduced quality of life and shortened life expectancy. Pro-AID investigates the current health care situation of children and adolescents with AID in Germany and the psychosocial burden of those affected and their families. Pro-AID is a prospective observational study that uses the structures of the national paediatric rheumatology database (NPRD). Over a total of 3 years, disease characteristics and disease activity as well as the therapy of children and adolescents with AID are recorded by physicians every six months within routine outpatient paediatric rheumatology appointments. Parents of affected children and adolescents as well as patients (12 years and older) report on their disease burden, family situation, psychosocial stress, and unmet needs as well as their satisfaction with the care they receive. The data are used to examine whether the patients are cared for according to the current recommendations of the Society for Paediatric Rheumatology and what the treatment results are. In addition, the subjective burden of disease (e.g. the quality of life of those affected, days absent from school), family burden and satisfaction with care are evaluated. Based on the information gained, measures for optimising the care of children and adolescents with AID will be developed with those affected and patient organisations. The knowledge gained shall be incorporated into future AID treatment recommendations.

Brief summary in scientific language

Autoinflammatory diseases (AID) are rare chronic diseases in which recurring or permanent inflammation occurs due to dysregulation of the innate immune system. Affected children and adolescents are at increased risk of comorbidities and socio-economic burden. Early effective treatment can prevent organ damage, reduced quality of life and shortened life expectancy. The Pro-AID project analyses the current health care situation of children and adolescents with AID and the psychosocial burden of affected patients and their families. Pro-AID is a prospective observational study incorporated in the national paediatric rheumatology database (NPRD). Over a total of three years, disease characteristics and activity as well as the treatment of children and adolescents with AID are recorded approximately every six months in routine care. Parents of affected children and adolescents as well as patients (aged 12 and over) report on their disease burden, family situation, psychosocial stress and unmet needs as well as their satisfaction with care. The primary study objective is to investigate whether patients are being treated in accordance with the current recommendations of the paediatric rheumatology society. The primary study outcome is disease activity. Secondary outcomes include the subjective burden of disease (e.g. quality of life of those affected, days missed from school), family burden and satisfaction with care. Based on the information obtained, measures to optimise the care of children and adolescents with AIDs are developed together with patient organisations. The knowledge gained will be incorporated into the further development of AID treatment recommendations.

Health condition or problem studied

Free text:
FMF (familial Mediterranean fever), NLRP3-AID (CAPS = Cryopyrin associated periodic syndromes), MKD (mevalonate kinase deficiency), TRAPS (TNF receptor associated periodic fever syndrome), PFAPA, DIRA (Deficiency of the IL-1 receptor antagonist), DITRA (Deficiency of the IL-36 receptor antagonist), NLRP12-AID (FCAS2 = Familial cold autoinflammatory syndrome 2), Aicardi-Goutières Syndrome (AGS), STING-Associated Vasculopathy with Onset in Infancy (SAVI), Chilblain Lupus, CANDLE (PRAAS) Syndrom, COPA Syndrome, Deficiency of Adenosine Deaminase 2 (DADA2), M. Behcet, unclassified and other AID
ICD10:
E85.0 - Non-neuropathic heredofamilial amyloidosis
ICD10:
M35.2 - Behçet disease
Free text:
ORPHA:210115 ORPHA:325004 ORPHA:342 ORPHA:32960 ORPHA:42642 ORPHA:247868 ORPHA:309025 ORPHA:51 ORPHA:404546 ORPHA:90280 ORPHA:117 ORPHA:425120 ORPHA:208650 ORPHA:444092
Healthy volunteers:
No

Interventions, Observational Groups

Arm 1:
Prospective observation of prevalent and incident cases with AID approximately every 6 months for a total of 24 months - Physician reports on diagnosis, age at onset of disease at baseline every 6 months on disease activity, therapy, clinical manifestations, concomitant diseases, selected laboratory parameters at the last visit, additionally on disease damage (using ADDI) - Patient/parent information on symptom onset, doctor contacts and time to diagnosis at baseline every 6 months on overall health, coping with illness, quality of life, family burden (FaBel), adherence to therapy, satisfaction with therapy

Endpoints

Primary outcome:
Disease activity (physician global assessment on a numerical rating scale of 0-10, NRS) at each visit
Secondary outcome:
Disease activity (patient global assessment on a numerical rating scale of 0-10) at each visit Damage (ADDI) at last visit Coping with disease, NRS, at each visit Quality of life (PedsQL 3.0 and 4.0, EQ-5D), at each visit Family burden (FaBel), at each visit Therapy adherence (JAMAR), at each visit Satisfaction with therapy (Likert scale), at each visit

Study Design

Purpose:
Health care system
Retrospective/prospective:
Prospective
Study type:
Non-interventional
Longitudinal/cross-sectional:
Longitudinal study
Study type non-interventional:
Epidemiological study

Recruitment

Recruitment Status:
Recruiting planned
Reason if recruiting stopped or withdrawn:
No Entry

Recruitment Locations

Recruitment countries:
  • Austria
  • Germany
Number of study centers:
Multicenter study
Recruitment location(s):
  • University medical center Kinderklinik der Medizinischen Hochschule Hannover Hannover
  • University medical center Klinik für Kinder- und Jugendmedizin Erlangen
  • Medical center Kinderklinik Amsterdamer Straße Köln
  • Medical center Asklepios Kinderklinik Sankt Augustin Sankt Augustin
  • Medical center St. Marien Krankenhaus Landshut
  • Medical center Olgahospital Stuttgart
  • Medical center St. Josef Stift Sendenhorst
  • Medical center Klinikum Bremen-Mitte Bremen
  • University medical center Klinik für Kinder- und Jugendmedizin Ulm
  • University medical center Dr. von Hauner'sches Kinderspital München
  • Medical center Kinderrheumaklinik Garmisch-Partenkirchen
  • University medical center Charité Berlin
  • University medical center Klinik für Kinder- und Jugendmedizin Tübingen
  • University medical center Department für Kinder- und Jugendmedizin Innsbruck

Recruitment period and number of participants

Planned study start date:
2024-01-15
Actual study start date:
No Entry
Planned study completion date:
2028-12-31
Actual Study Completion Date:
No Entry
Target Sample Size:
250
Final Sample Size:
No Entry

Inclusion Criteria

Sex:
All
Minimum Age:
no minimum age
Maximum Age:
18 Years
Additional Inclusion Criteria:
- autoinflammatory disease diagnosed by paediatric rheumatologist - written informed consent

Exclusion Criteria

- Lack of cognitive maturity to understand the requirements and content of the project - Diagnoses: systemic JIA, CRMO

Addresses

Primary Sponsor

Address:
Deutsches Rheuma-Foschungszentrum Berlin
10117 Berlin
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry
Investigator Sponsored/Initiated Trial (IST/IIT):
Yes

Contact for Scientific Queries

Address:
Deutsches Rheuma-Forschungszentrum Berlin
Dr. med. Tatjana Welzel
Charitéplatz 1
10117 Berlin
Germany
Telephone:
+493028460632
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Contact for Public Queries

Address:
Deutsches Rheuma-Forschungszentrum Berlin
Dr. med. Tatjana Welzel
Charitéplatz 1
10117 Berlin
Germany
Telephone:
+493028460632
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Principal Investigator

Address:
Deutsches Rheuma-Forschungszentrum Berlin
Prof. Dr. med. Kirsten Minden
Charitéplatz 1
10117 Berlin
Germany
Telephone:
+493028460669
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
https://www.drfz.de

Sources of Monetary or Material Support

Private sponsorship (foundations, study societies, etc.)

Address:
Kindness for Kids - Stiftung für Kinder mit Seltenen Erkrankungen
82319 Starnberg
Germany
Telephone:
No Entry
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
No Entry

Ethics Committee

Address Ethics Committee

Address:
Ethik-Kommission an der Medizinischen Fakultät der RWTH Aachen
Wendlingweg 2
52074 Aachen
Germany
Telephone:
+49-241-8089963
Fax:
No Entry
Contact per E-Mail:
Contact per E-Mail
URL:
http://www.medizin.rwth-aachen.de/cms/Medizin/Die-Fakultaet/Organisation/~coeq/Ethik-Kommission/

Vote of leading Ethics Committee

Vote of leading Ethics Committee
Date of ethics committee application:
2023-06-20
Ethics committee number:
EK 384/19
Vote of the Ethics Committee:
Approved
Date of the vote:
2023-10-27

Further identification numbers

Other primary registry ID:
No Entry
EudraCT Number:
No Entry
UTN (Universal Trial Number):
No Entry
EUDAMED Number:
No Entry

IPD - Individual Participant Data

Do you plan to make participant-related data (IPD) available to other researchers in an anonymized form?:
No
IPD Sharing Plan:
No Entry

Study protocol and other study documents

Study protocols:
No Entry
Study abstract:
No Entry
Other study documents:
No Entry
Background literature:
No Entry
Related DRKS studies:
No Entry

Publication of study results

Planned publication:
No Entry
Publikationen/Studienergebnisse:
No Entry
Date of first publication of study results:
No Entry
DRKS entry published for the first time with results:
No Entry

Basic reporting

Basic Reporting / Results tables:
No Entry
Brief summary of results:
No Entry